63
https://pubmed.ncbi.nlm.nih.gov/38117098
FES PET/CT, used for imaging estrogen receptor-positive breast cancer, is increasing in clinical use, but its role in endocrine therapy selection, negative results follow-up, and ER-expressing nonbreast malignancies is still a matter of controversy.